Cellectricon Launches Neuroinflammation Research Service

Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, has launched the Neuroinflammation Research Service module designed to expedite the development of treatments for neurodegenerative and neuropsychiatric disorders. The service has been refined and extensively tested over three years with several pharma and biopharma clients.
 
Evidence suggests that inflammatory responses in the CNS play a key role in the progression of a broad range of diseases, modulating both neurotoxic and neuroprotective activity. Understanding the relationship between neuroinflammation and disease development is therefore crucial for the discovery of effective therapies, however until now there has been a lack of relevant in vitro models. 
 
With its experience in the development of standardized, advanced in vitro cultures, Cellectricon’s Neuroinflammation Research Service is establishing both chimeric and fully humanized in vitro disease models to accurately mimic various aspects of acute and chronic neuroinflammation. 
 
 “Working in a true collaborative fashion with Cellectricon has enabled us to establish advanced in vitro platforms amenable for neuroinflammatory compound screening,” said Dr. Jonathan Levenson, CSO at FireCyte Therapeutics. “This has helped us progress our work to develop new treatments for progressive neurodegenerative diseases of the eye.”